Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 2634 • ACR Convergence 2024
Transcriptomic Stratification Predicts Response to Rituximab, Abatacept or the Association of Hydroxychloroquine and Leflunomide in 3 Randomized Controlled Clinical Trials in Sjögren’s Disease
Baptiste Chevet¹, Valerie Devauchelle², Elena Pontarini³, Valentin Baloche⁴, Michele Bombardieri⁵, Simon Bowman⁶, Michael Barnes⁷, Antoine Sreih⁸, Jinqi Liu⁸, Sheila Kelly⁹, Antonia Christodoulou⁸, Hussain Badani¹⁰, Philippe Moigeon¹¹, Laurence LAIGLE¹², Perrine Soret¹³, Christelle Le dantec¹⁴, Jacques-Olivier Pers¹⁵, Marta Alarcon-Riquelme¹⁶, Guillermo Barturen¹⁷, Xavier Mariette¹⁸, Joel Van Roon¹⁹, Raphaele Seror²⁰, Gaetane Nocturne¹⁸, Divi Cornec²¹ and Nathan Foulquier¹⁴, and PRECSEADS Clinical Consortium and NECESSITY consortium, ¹University Hospital of Brest, Brest, France, ²UBO, Brest, France, ³William Harvey Research Institute, London, United Kingdom, ⁴University Medical Center, Utrecht, Utrecht, Netherlands, ⁵Centre for Experimental Medicine and Rheumatology, The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ⁶Department of Rheumatology, University Hospital Birmingham, Birmingham, United Kingdom, ⁷William Harvey Research institute, Centre for Translational Bioinformatics, London, United Kingdom, ⁸Bristol Myers Squibb, Princeton, NJ, ⁹Bristol Myers Squibb, Doylestown, PA, ¹⁰Bristol Myers Squibb, Lawrence Township, NJ, ¹¹Servier Laboratories, France, Gif sur Yvette, France, ¹²Servier Laboratories, France, SURESNES, France, ¹³Servier, Paris-Saclay, Paris, Ile-de-France, France, ¹⁴LBAI. UMR 1227, University of Brest, Brest, France, ¹⁵University of Brest, Brest, France, ¹⁶Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹⁷Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ¹⁸Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ¹⁹University Medical Center Utrecht, Utrecht, Netherlands, ²⁰Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ²¹Service de Rhumatologie, CHU de Brest, Brest, France
Background/Purpose: Sjögren’s disease (SjD) is a clinically and biologically heterogeneous disease. To date, no phase-III trial showed efficacy in reducing the symptoms or systemic activity…
Abstract Number: 0152 • ACR Convergence 2024
Hydroxychloroquine and Chloroquine Retinopathy in Hispanic Patients with Rheumatic Diseases
Janett Riega Torres¹, Karina Palomo-Arnaud², Gabriel Figueroa-Parra¹, Fernando Morales Wong¹, Jesús Hernán González Cortés¹, Jesus Mohamed Hamsho¹, Jorge Esquivel-Valerio¹, Dionicio Galarza-Delgado³ and Karim Mohamed Noriega¹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, ³UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Antimalarial drugs like hydroxychloroquine (HCQ) and chloroquine (CQ) are among the most frequently prescribed medications in Rheumatology. Retinal toxicity is an unwanted side effect…
Abstract Number: 1411 • ACR Convergence 2024
Impact of Patient and Physician Alignment on Sjögren’s Disease Severity, a Real-World Survey on Patients’ Clinical Outcomes and Health-Related Quality of Life
Wan Fai Ng¹, Coralie Bouillot², NICOLA MASSEY³, Megan Hughes³, Victoria Barton³, Giorgio Castellano³, Ana Barat⁴, Gayle Kenney⁵ and Jessica Marvel⁶, ¹Department of Rheumatology, Newcastle University, & HRB Clinical Research Facility, University College Cork, Newcastle upon Tyne, United Kingdom, ²Sjögren Europe, Switzerland, Switzerland, ³ADELPHI REAL WORLD, BOLLINGTON, United Kingdom, ⁴Novartis Ireland Ltd, Dublin, Ireland, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis, East Hanover, NJ
Background/Purpose: Sjögren’s disease (SjD) has a high disease burden in affected patients, with no licensed treatments currently available. The Clinical EULAR Sjögren’s syndrome disease activity…
Abstract Number: 1427 • ACR Convergence 2024
Observed and Simulated Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Fully Human FcRn Blocking Monoclonal Antibody, in Adults with Sjögren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study
Sophia G. Liva¹, fudan Zheng¹, Jocelyn H. Leu², Kathy Sivils³, Keying Ma¹, He Li⁴, Steven Leonardo⁵, Kim Lo¹, Jada Idokogi¹, Kim Campbell¹ and Jonathan J. Hubbard¹, ¹Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA, ³Johnson & Johnson Innovative Medicine, Edmond, OK, ⁴Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, ⁵Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA
Background/Purpose: Sjögren’s disease (SjD) is a chronic, progressive autoimmune disease characterized by aberrant B lymphocyte activity, elevated IgG production, and the presence of IgG autoantibodies…
Abstract Number: 2289 • ACR Convergence 2024
Associations Between Protein Quantitative Trait Loci and Risk of Primary Sjögren’s Syndrome: A Mendelian Randomization Study
Benjamin Zuckerman¹, Alasdair Warwick², art Schuermans³, Mark Gibson⁴, Ioasaf Karafotias⁵, Zijing Yang¹, Carine moezinia⁶, Mark Russell⁷, Chris Wincup⁸, James Galloway⁹ and Sizheng Zhao¹⁰, ¹King's College London, London, England, United Kingdom, ²University college London, London, United Kingdom, ³KU Leuven, Leuven, Belgium, ⁴King's College London, Newmarket, United Kingdom, ⁵King's College London, London, United Kingdom, ⁶univerity college hospital, London, United Kingdom, ⁷King's College London, London, United Kingdom, ⁸King's College Hospital, London, United Kingdom, ⁹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ¹⁰Centre for Musculoskeletal Research, The University of Manchester, Liverpool, United Kingdom
Background/Purpose: The pathophysiology of primary Sjögren’s disease involves the interaction of genetic, epigenetic, and environmental factors. With limited treatment options for severe disease, a detailed understanding…
Abstract Number: 2305 • ACR Convergence 2024
Anti-Ku Positivity in Primary Sjögren’s Disease Is Associated with a More Systemic Active Disease
Marie ROBERT¹, Yann Nguyen², Yurdagül Uzunhan³, Benjamin Terrier⁴, Yves Allenbach⁵, Alain Meyer⁶, Jacques-Eric Gottenberg⁷, JEROME HADJADJ⁸, Zahir Amoura⁹, ARNAUD HOT¹⁰, Eléonore Bettacchioli¹¹, Elisabeth Aslangul¹², Rakiba Belkhir¹³, Frederic Desmoulins¹⁴, Elisabeth Bergé¹⁴, Pascale Chrétien¹⁵, Pascale Roland-Nicaise¹⁶, Claire Goulvestre¹⁷, Jean-Luc Charuel¹⁸, Benoit Nespola¹⁹, Nicole Fabien²⁰, Eric Ballot²¹, Gaetane Nocturne¹⁴, Xavier Mariette¹⁴, Samuel Bitoun¹ and Raphaele Seror²², ¹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, ²Université Paris Saclay, Clichy, Ile-de-France, France, ³Service de Pneumologie, Hôpital Avicenne, AP-HP, Bobigny, France, ⁴Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁵Service de Médecine interne et immunologie clinique, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France, ⁶UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, ⁷Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ⁸Service de Médecine interne, Hôpital Saint-Antoine, AP-HP, Paris, Ile-de-France, France, ⁹French National Reference Centre for Systemic Lupus Erythematosus, Pitié-Salpêtrière Hospital, Paris, France, ¹⁰Service de Médecine interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France, ¹¹Service de Rhumatologie, CHU de Brest, Brest, France, ¹²Service de Médecine interne, Hôpital Louis Mourier, AP-HP, Colombes, France, ¹³Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France, ¹⁴Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ¹⁵Laboratoire d'immunologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, France, ¹⁶Laboratoire d'immunologie, Hôpital Bichat, AP-HP, Paris, France, ¹⁷Laboratoire d'immunologie, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ¹⁸Laboratoire d'immunologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France, ¹⁹Laboratoire d’immunologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²⁰Laboratoire d'immunologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France, ²¹Laboratoire d'immunologie, Hôpital Saint-Antoine, AP-HP, Paris, Ile-de-France, France, ²²Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France
Background/Purpose: Sjögren’s disease (SjD) is an autoimmune disease characterized by a wide range of symptoms, and 30% to 60% of patients developed systemic manifestations. The…
Abstract Number: 2664 • ACR Convergence 2024
BCMA-targeted Bispecific T Cell-engager Therapy of Autoimmune Disease
Laura Bucci¹, Melanie Hagen², Sebastian Boeltz², Danae-Mona Noethling², Tobias Rothe², Maria Gabriella Raimondo¹, Carlo Tur¹, Andreas Wirsching¹, Jochen Wacker¹, Aline Bozec¹, Georg Schett³ and Ricardo Grieshaber-Bouyer², ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Targeting B cells and plasma cells is a key therapeutic strategy in autoimmune disease(AID). Therapy with CD19-targeted chimeric antigen receptor (CAR) T-cells and bi-specific…
Abstract Number: 0154 • ACR Convergence 2024
Chronic Sinusitis Predicting Interstitial Lung Disease in Sjögren’s Syndrome: A Comprehensive USA Population Study (2004-2024)
Brian Schonewald¹, Ross summer², Giorgos Loizidis² and Christopher Xie³, ¹Thomas Jefferson University Hospital, Ardmore, PA, ²Thomas Jefferson University, Philadelphia, PA, ³Thomas Jefferson University, Philadelphia
Background/Purpose: Sjögren's syndrome (SS) is a chronic autoimmune disorder primarily affecting the exocrine glands, but it also impacts various parts of the respiratory system, including…
Abstract Number: 1412 • ACR Convergence 2024
Survival and Predictive Markers of Prognosis in Patients with Cancer Occurrence After Sjögren Syndrome: A Long-term Observational Study
Yezi Peng¹, Jiana Chen², Yafei Ren³, Dan Yang², Xiangyi Shen⁴, Xu Jiang⁵ and Huaxia Yang², ¹Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Dong Cheng Qu, Beijing, China (People's Republic), ²Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Department of Rheumatology and immunotogy,Affiliated Hospital of Guilin Medical University,Guilin, China, Guangxi, China (People's Republic), ⁴Tsinghua University, Beijing, China, ⁵National Infrastructure for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Background/Purpose: Patients with Sjögren syndrome (SS) have been reported to have a higher risk of cancer than the general population, and malignancy constitutes one of…
Abstract Number: 1428 • ACR Convergence 2024
A Post-hoc Analysis of Two Phase 2 Randomized Controlled Trials in Patients with Active Sjogren’s Disease Exploring the Novel Composite Endpoint Sjögren’s Tool for Assessing Response (STAR)
Wolfgang Hueber¹, Raphaele Seror², Raphael Porcher³, Gabriel Baron⁴, Linchen He⁵, Wen-Lin Luo⁵, Xavier Mariette⁶ and Peter Gergely¹, and the members of the NECESSITY IMI2 consortium, ¹Novartis Pharma, Basel, Switzerland, ²Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ³Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, ⁴Hôpitaux Universitaires Paris-Sud (AP-HP), Paris, Ile-de-France, France, ⁵Novartis Pharma, East Hanover, NJ, ⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France
Background/Purpose: Two randomized controlled phase 2 trials in patients with active Sjogren’s disease (SjD) were recently completed, the LOUiSSe trial assessing the Bruton Tyrosine kinase…
Abstract Number: 2290 • ACR Convergence 2024
Umbilical Cord-derived Mesenchymal Stem Cells Suppress Sjogren’s Syndrome Pathology
Yukitomo Hagiwara¹, Goh Murayama², Taiga Kuga², Yujin Nishioka², Takumi Saito², Yu Yamaji², Tomoko Miyashita², Makio Kusaoi³, Ken Yamaji² and Naoto Tamura², ¹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan, ²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyo, Tokyo, Japan
Background/Purpose: Primary Sjögren's syndrome (pSS) is characterized by lymphocytic infiltration of the salivary and lacrimal glands, leading to functional loss and gradually causing dry mouth…
Abstract Number: 2306 • ACR Convergence 2024
Deconstruction and Reconstruction of Sjögren’s Disease: AMP®-AIM Partnership
Astrid Rasmussen¹, A. Darise Farris¹, Alan Baer², Blake M. Warner³, Christopher Lessard¹, Stephen Shiboski⁴ and Caroline Shiboski⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³National Institutes of Health, Bethesda, MD, ⁴University of California San Francisco, San Francisco, CA
Background/Purpose: The Accelerating Medicines Partnership (AMP®) is a public-private partnership with the goal of transforming the current model for developing new diagnostics and treatments by…
Abstract Number: PP09 • ACR Convergence 2024
Finding the Balance: Regaining My Strength While Living with Sjögren’s & POTS
Robert Fearon, Sjögren's Foundation, Reston, VA
Background/Purpose: Like many suffering from autoimmune diseases, my diagnosis was not straightforward and took nearly 13 years to get answers. I first started experiencing an…
Abstract Number: 0443 • ACR Convergence 2024
Significance of anti-Ro52 Antibody in Pregnancy Complicated with Anti-SS-A Antibody Positive Rheumatic Disease Patients
Hiromi Shimada¹, Rina Mino², taichi miyagi³, Yusuke Ushio⁴, Koichi Sugihara⁵, Mao Mizusaki², Hayamasa yamaguchi², Naoto Manabe², Shusaku Nakashima¹ and Hiroaki Dobashi¹, ¹Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ²Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, kidagun, Japan, ⁴Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, ⁵Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa Prefecture, Japan
Background/Purpose: Anti-SS-A antibodies are associated with neonatal lupus erythematosus and congenital heart block (CHB). Ro/SS-A autoantigen is comprised of 52kDa Ro (Ro52) and 60kDa Ro…
Abstract Number: 1413 • ACR Convergence 2024
Pilot Trial of Ustekinumab for Primary Sjogren’s Syndrome
Ummara Shah¹ and Andrea Coca², ¹University of Rochester, Webster, NY, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Sjogren’s Syndrome (SS) is a chronic autoimmune disease characterized by keratoconjunctivitis sicca and xerostomia. Currently there is no approved systemic treatment for primary SS. …

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.